Wenfeng Luo

Dr. Wenfeng Luo

orcid

Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
31 May 2023 in Journal of Cellular and Molecular Medicine
Verified
Journal Article
Open access
WLWenfeng Luo
Wenfeng Luo
JDJie Deng
Jie Deng
JHJiecheng He
Jiecheng He
LYLiang Yin
Liang Yin
RYRong You
Rong You
YGYan-Qin Guan
Yan-Qin Guan
Fenugreek is an ancient herb that has been used for centuries to treat diabetes. However, how the fenugreek‐derived chemical compounds work in treating diabetes remains unclarified. Herein, we integrate molecular docking and network pharmacology to elucidate the active constituents and potential mechanisms of fenugreek against diabetes. First, 19 active compounds from fenugreek and 71 key diabetes‐related targets were identified through network pharmacology analysis. Then, molecular docking and simulations results suggest diosgenin, luteolin and quercetin against diabetes via regulation of the genes ESR1, CAV1, VEGFA, TP53, CAT, AKT1, IL6 and IL1. These compounds and genes may be key factors of fenugreek in treating diabetes. Cells results demonstrate that fenugreek has good biological safety and can effectively improve the glucose consumption of IR‐HepG2 cells. Pathway enrichment analysis revealed that the anti‐diabetic effect of fenugreek was regulated by the AGE‐RAGE and NF‐κB signalling pathways. It is mainly associated with anti‐oxidative stress, anti‐inflammatory response and β‐cell protection. Our study identified the active constituents and potential signalling pathways involved in the anti‐diabetic effect of fenugreek. These findings provide a theoretical basis for understanding the mechanism of the anti‐diabetic effect of fenugreek. Finally, this study may help for developing anti‐diabetic dietary supplements or drugs based on fenugreek.

1 April 2018 in Materials Research Express
Verified
Journal Article
Closed access
PDF file
WLWenfeng Luo
Wenfeng Luo
SZShuangying Zhang
Shuangying Zhang
YLYuewei Lan
Yuewei Lan
CHChen Huang
Chen Huang
CWChao Wang
Chao Wang
NANingjian Ao
Ningjian Ao

19 September 2024 in Frontiers in Nutrition
Verified
Journal Article
Open access
PDF file
JDJie Deng
Jie Deng
KZKai Zhou
Kai Zhou
CFCaimin Feng
Caimin Feng
YBYilu Bao
Yilu Bao
ZZZhiming Zhang
Zhiming Zhang
MLMeiying Li
Meiying Li
Background: The disorder of uric acid metabolism is closely associated with gut microbiota and short-chain fatty acids (SCFAs) dysregulation, but the biological mechanism is unclear, limiting the development of uric acid-lowering active polysaccharides. Konjac glucomannan (KGM) could attenuate metabolic disturbance of uric acid and modulate the gut microbiota. However, the relationship between uric acid metabolism and gut microbiota is still unknown.Methods: In this study, The fecal samples were provided by healthy volunteers and hyperuricemia (HUA) patients. Fecal samples from healthy volunteers was regarded as the NOR group. Similarly, 10% HUA fecal suspension was named as the HUA group. Then, fecal supernatant was inoculated into a growth basal medium containing glucose or KGM, and healthy fecal samples were designated as the NOR-GLU and NOR-KGM groups, while HUA fecal samples were designated as the HUA-GLU and HUA-KGM groups. All samples were cultured in an anaerobic bag system. After fermentation for 24 h, the samples were collected for further analysis of composition of intestinal microbiota, SCFAs concentration and XOD enzyme activity.Results: The results showed that KGM could be utilized and degraded by the gut microbiota from HUA subjects, and it could modulate the composition and structure of their HUA gut microbiota to more closely resemble that of a healthy group. In addition, KGM showed a superior modulated effect on HUA gut microbiota by increasing Megasphaera, Faecalibacterium, Lachnoclostridium, Lachnospiraceae, Anaerostipes, and Ruminococcus levels and decreasing Butyricicoccus, Eisenbergiella, and Enterococcus levels. Furthermore, the fermentation solution of KGM showed an inhibitory effect on xanthine oxidase (XOD) enzyme activity, which might be due to metabolites such as SCFAs.Conclusion: In conclusion, the effect of KGM on hyperuricemia subjects was investigated based on the gut microbiota in vitro. In the present study. It was found that KGM could be metabolized into SCFAs by HUA gut microbiota. Furthermore, KGM could modulate the structure of HUA gut microbiota. At the genus level, KGM could decrease the relative abundances of Butyricicoccus, Eisenbergiella, and Enterococcus, while Lachnoclostridium and Lachnospiraceae in HUA gut microbiota were significantly increased by the addition of KGM. The metabolites of gut microbiota, such as SCFAs, might be responsible for the inhibition of XOD activity. Thus, KGM exhibited a superior probiotic function on the HUA gut microbiota, which is expected as a promising candidate for remodeling the HUA gut microbiota.

22 September 2022 in Colloids and Surfaces B: Biointerfaces
Verified
Journal Article
Closed access
MXMingze Xu
Mingze Xu
HQHan Qin
Han Qin
YZyuxin zheng
yuxin zheng
JCJiapeng Chen
Jiapeng Chen
XLXuanxi Liang
Xuanxi Liang
GYGuan Yan-Qing
Guan Yan-Qing

11 July 2020 in Chemnanomat
Verified
Journal Article
Closed access
PDF file
CWChong Wang
Chong Wang
ZWZiyan Wu
Ziyan Wu
Xiaohui LiXiaohui Li
Xiaohui Li
JFJiangjiang Feng
Jiangjiang Feng
WLWenfeng Luo
Wenfeng Luo
TSTikang Shu
Tikang Shu

4 January 2019 in Drug Delivery and Translational Research
Verified
Journal Article
Open access
PDF file
CHchen huang
chen huang
XHXueping He
Xueping He
WLWenfeng Luo
Wenfeng Luo
HCHanwei Chen
Hanwei Chen
YHYi Huang
Yi Huang
To prospectively study the efficacy of different anti-adhesion agents for the prevention of tubal obstruction after recanalization, this trial was approved by our hospital ethics committee. Four hundred patients with fallopian tube obstruction were randomly assigned to four groups. The control group underwent recanalization alone, whereas the other groups were injected with chitosan, Dan-shen, or combined chitosan and Dan-shen after recanalization. The tubal patency rate in all four groups was recorded after 12 day, 3 months, and 12 months. The pregnancy rates were noted after 12 months. The recanalization rates after 1 day in the control, chitosan, Dan-shen, and combined chitosan and Dan-shen groups were 94.1, 97.1, 96.5, and 98.2%, respectively (p = 0.18, p > 0.05). The rates of tubal patency after 3 months were significantly higher in the combined chitosan and Dan-shen (96.5%), chitosan (88%), and Dan-shen (85.2%) groups compared with the control group (73.9%) (p = 0.0001, p < 0.05). The recanalization rate and intrauterine pregnancy rate after 12 months was significantly higher in the combined chitosan and Dan-shen group (93.8 and 63.9%, respectively) compared with the other groups (control 39 and 30.6%, chitosan 78.4 and 46.9%, and Dan-shen 77.3 and 43.3%) (p = 0.0029 and p = 0.0001, p < 0.05). Chitosan, Dan-shen, or a combination of the two compounds could be effective for preventing tubal obstruction after interventional recanalization, possibly increasing the rate of pregnancy in affected women. The combined chitosan and Dan-shen injection has unique advantages in the interventional recanalization of obstructed fallopian tubes.